Literature DB >> 18566479

A high-throughput screen for endothelial lipase using HDL as substrate.

Paul M Keller1, Timothy Rust, Dennis J Murphy, Rosalie Matico, John J Trill, John A Krawiec, Anthony Jurewicz, Michael Jaye, Mark Harpel, Sara Thrall, Benjamin Schwartz.   

Abstract

Endothelial lipase (EL) is a 482-amino-acid protein from the triglyceride lipase gene family that uses a Ser-His-Asp triad for catalysis. Its expression in endothelial cells and preference for phospholipids rather than triglycerides are unique. Animal models in which it is overexpressed or knocked out indicate EL levels are inversely correlated with high-density lipoprotein cholesterol (HDL-C). HDL-C is commonly referred to as the good form of cholesterol because it is involved in the reverse cholesterol transport pathway, in which excess cholesterol is effluxed from peripheral tissues for excretion or reabsorption. Thus, EL inhibition in humans is expected to lead to increases in HDL levels and possibly a decrease in cardiovascular disease. To discover inhibitors of EL, a coupled assay for EL has been developed, using its native substrate, HDL. Hydrolysis of HDL by EL yields free fatty acids, which are coupled through acyl-CoA synthetase, acyl-CoA oxidase, and horseradish peroxidase to produce the fluorescent species resorufin. This assay was developed into a 5-microL, 1536-well assay format, and a high-throughput screen was executed against the GSK collection. In addition to describing the screening results, novel post-HTS mechanism-of-action studies were developed for EL and applied to 1 of the screening hits as an example.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18566479     DOI: 10.1177/1087057108319738

Source DB:  PubMed          Journal:  J Biomol Screen        ISSN: 1087-0571


  5 in total

1.  Endocytosis of very low-density lipoproteins: an unexpected mechanism for lipid acquisition by breast cancer cells.

Authors:  Leslie E Lupien; Katarzyna Bloch; Jonas Dehairs; Nicole A Traphagen; William W Feng; Wilson L Davis; Thea Dennis; Johannes V Swinnen; Wendy A Wells; Nicole C Smits; Nancy B Kuemmerle; Todd W Miller; William B Kinlaw
Journal:  J Lipid Res       Date:  2019-12-05       Impact factor: 5.922

2.  An Inhibitor of Fatty Acid Synthase Thioesterase Domain with Improved Cytotoxicity against Breast Cancer Cells and Stability in Plasma.

Authors:  Leslie E Lupien; Evan M Dunkley; Margaret J Maloy; Ian B Lehner; Maxwell G Foisey; Maddison E Ouellette; Lionel D Lewis; Darcy Bates Pooler; William B Kinlaw; Paul W Baures
Journal:  J Pharmacol Exp Ther       Date:  2019-07-12       Impact factor: 4.030

3.  A novel fluorogenic substrate for the measurement of endothelial lipase activity.

Authors:  Andrew L Darrow; Matthew W Olson; Hong Xin; Sharon L Burke; Charles Smith; Celine Schalk-Hihi; Robyn Williams; Shariff S Bayoumy; Ingrid C Deckman; Matthew J Todd; Bruce P Damiano; Margery A Connelly
Journal:  J Lipid Res       Date:  2011-02       Impact factor: 5.922

4.  PK/PD Disconnect Observed with a Reversible Endothelial Lipase Inhibitor.

Authors:  Jon J Hangeland; Lynn M Abell; Leonard P Adam; Ji Jiang; Todd J Friends; Lauren E Haque; James Neels; Joelle M Onorato; Alice Ye A Chen; David S Taylor; Xiaohong Yin; Thomas W Harrity; Michael D Basso; Richard Yang; Paul G Sleph; David A Gordon; Christine S Huang; Ruth R Wexler; Heather J Finlay; R Michael Lawrence
Journal:  ACS Med Chem Lett       Date:  2018-06-15       Impact factor: 4.345

5.  Measurement of the phospholipase activity of endothelial lipase in mouse plasma.

Authors:  Debapriya Basu; Xia Lei; Joby Josekutty; M Mahmood Hussain; Weijun Jin
Journal:  J Lipid Res       Date:  2012-10-26       Impact factor: 5.922

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.